

ARTICLE

Open Access

# Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma

Xiaoyang Li<sup>1,2</sup>, Nicole A. Seebacher<sup>1</sup>, Cassandra Garbutt<sup>3</sup>, Hangzhan Ma<sup>1</sup>, Peng Gao<sup>1</sup>, Tao Xiao<sup>2</sup>, Francis J. Hornicek<sup>1</sup> and Zhenfeng Duan<sup>1</sup>

## Abstract

Synovial sarcoma is a highly aggressive but rare form of soft tissue malignancy that primarily affects the extremities of the arms or legs, for which current chemotherapeutic agents have not been proven to be very effective. The cyclin-dependent kinase 4/6-retinoblastoma protein (CDK4/6-Rb) pathway of cell cycle control is known to be aberrant in a large proportion of cancers. Recently, CDK4 inhibitors have successfully been used pre-clinically for the treatment of many human cancers, and in 2015, following the success of clinical trials, the FDA approved the first selective CDK4/6 inhibitor, palbociclib, for the treatment of endocrine therapy resistant breast cancers. However, the expression and therapeutic potential of targeting CDK4 in synovial sarcoma remains unclear. In the present study, we report that CDK4 is highly expressed in human synovial sarcoma, and high CDK4 expressions are associated with poor prognosis in sarcomas patients and the clinical stage and the TNM grade in synovial sarcoma patients. Knockdown of CDK4 with specific small interference RNAs inhibits cell proliferation and enhances apoptotic effects in synovial sarcoma cells. CDK4 inhibitor palbociclib suppresses synovial sarcoma cell proliferation and growth in a dose and time-dependent manner. Palbociclib also inhibits the CDK4/6-Rb signaling pathway and promotes cell apoptosis without changing CDK4/6 protein levels, suggesting that palbociclib only represses the hyper-activation, not the expression of CDK4/6. Flow cytometry analysis reveals that palbociclib induces G1 cell-cycle arrest and apoptotic effects by targeting the CDK4/6-Rb pathway in synovial sarcoma cells. Furthermore, wound healing assays demonstrate that inhibition of the CDK4/6-Rb pathway by palbociclib significantly decreases synovial sarcoma cell migration in vitro. Our study highlights the importance of the CDK4/6-Rb pathway in human synovial sarcoma pathogenesis, and the role of the current selective CDK4/6 inhibitor, palbociclib, as a potential promising targeted therapeutic agent in the treatment of human synovial sarcoma.

## Introduction

Synovial sarcoma (SS) is a high-grade subtype of soft tissue sarcoma that occurs mainly in children and young adults, characterized by the chromosomal translocation

t(X;18) (p11.2; q11.2)<sup>1–3</sup>. The current treatment for localized synovial sarcoma is surgery, occasionally with the combination of additional radiotherapy and chemotherapy, and the published five-year survival rate varies from 40% to 60%<sup>4,5</sup>. However, once the primary disease advances with pulmonary metastasis and relapse, the prognosis is poor, even if under the intensive multi-agent chemotherapy. The limited availability of effective therapeutic measures indicates an urgent clinical need for novel alternative treatment strategies for patients with synovial sarcoma.

Correspondence: Zhenfeng Duan (zduan@mednet.ucla.edu)

<sup>1</sup>Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, David Geffen School of Medicine at University of Los Angeles, Los Angeles, CA 90095, USA

<sup>2</sup>Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China

Full list of author information is available at the end of the article

Edited by S. Tait

© The Author(s) 2018



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

Aberrations in cell cycle control is defined as one of the hallmarks of cancer, and may be a favorable target for the improvement of new therapeutic options for the treatment of sarcoma<sup>6,7</sup>. As one of the essential signaling pathways involved in cell cycle progression, the cyclin-dependent kinase (CDK) 4/6-retinoblastoma protein (Rb) pathway (CDK4/6-Rb pathway) is frequently found to be aberrant in cancer<sup>8</sup>. CDK4 is one of the serine/threonine (Ser/Thr) protein kinases that mediates cell cycle progression through the G1-S phase, in preparation for DNA synthesis<sup>9</sup>. The heterodimers formed by CDK4, or its close homolog CDK6, with D-type cyclins (cyclin D) are critical for cell cycle progression. In human malignancies, CDK4 associates with cyclin D and regulates the cell cycle through hyperphosphorylation and deactivation of the tumor suppressor retinoblastoma protein (Rb)<sup>10,11</sup>. Specifically, in response to pro-proliferative stimuli, cyclin D1 associates with CDK4 and gains access to the nuclear cyclin D1-CDK4 complex<sup>12</sup>. These active cyclin D/CDK4 complexes induce the phosphorylation of Rb, and thereby switch off the tumor suppressing function of Rb<sup>13</sup>. The hyperphosphorylated form of Rb is no longer able to bind with the transcription factor E2F1, leading to cancer cell cycle progression through activated transcription of various cell-cycle and anti-apoptotic genes<sup>14,15</sup>. Activation and amplification of the cyclin D/CDK4/Rb pathway has been shown to correlate with uncontrolled tumor cell growth and proliferation in various types of malignancies, including in sarcoma<sup>16</sup>.

CDK4/6 specific inhibitors are the most clinically advanced type of CDK inhibitor, and notably, a dual CDK4/6 inhibitor, palbociclib (IBRANCE®). Although palbociclib was initially developed to target the ATP-binding site of CDK4, due to the high homologous and structural similarities between CDK4 and CDK6, palbociclib also targets CDK6. Palbociclib was the first drug in this class to receive Food and Drug Administration (FDA) approval as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor, letrozole, or the selective estrogen receptor downregulator, fulvestrant<sup>17–21</sup>. The FDA have since also approved the CDK4/6 inhibitors, ribociclib (KISQALI®) and abemaciclib (Verzenio™), for a similar application<sup>22</sup>. These agents have also been investigated in other solid tumors, ranging from melanoma to non-small cell lung cancer<sup>23,24</sup>.

Although the field of targeted-therapy for carcinomas is growing rapidly, trials with targeted treatment for rare cancers, such as sarcomas, remain scarce. Interestingly, palbociclib is currently registered in a phase II clinical trial for patients with well-differentiated or dedifferentiated liposarcoma<sup>25,26</sup>. A recent study has reported that nuclear

phosphorylated Rb (pRb) expression may be correlated with a poor prognosis for synovial sarcoma patients, and put forward for consideration the potential of palbociclib for patient treatment<sup>27</sup>. However, as a critical part of the Cyclin D/CDK4/6/Rb axis, the expression and clinical significance of CDK4, and the potential mechanism of targeting CDK4 using the specific inhibitor palbociclib as a putative therapeutic strategy, remains to be elucidated in synovial sarcoma. Therefore, in this study, we evaluate the expression of CDK4 and its therapeutic applications in human synovial sarcoma, as well as test palbociclib as a possible treatment for synovial sarcoma.

## Results


### CDK4 is highly expressed in human synovial sarcoma cell lines

As demonstrated by western blotting, all these human synovial sarcoma cell lines exhibit high levels of CDK4 expression (Fig. 1a). We also assessed the expression of CDK6, cyclin D1, p16<sup>INK4A</sup>, Bcl-xL, Rb and phosphorylated Rb (pRb: Ser795, 780 and 807/811). All of the four synovial sarcoma cell lines also expressed cyclin D1, pRb, Rb, and Bcl-xL (Fig. 1a). In contrast, none of these cell lines expressed p16<sup>INK4A</sup>. CDK6 was highly expressed in the SYO-1 and Yamato cell lines, but was undetectable in the Fuji and Aska cell lines (Fig. 1a). Relative expressions of CDK4 and CDK6 were compared with  $\beta$ -actin in different synovial sarcoma cell lines (Fig. 1b). To further assess the subcellular localization of CDK4 in synovial sarcoma cells, immunofluorescence was performed in SYO-1 and Fuji cells. The green staining represents the CDK4 protein, and the red staining represents  $\beta$ -Actin in the cellular cytoplasm. As shown, CDK4 protein is mostly localized in the nucleus of synovial sarcoma cells, but with some localized to the cytoplasm (Fig. 1c).

### CDK4 expression levels correlates with the clinicopathological characteristics of synovial sarcoma patients

To further validate the clinical significance of CDK4 expression in patients with synovial sarcoma, we tested the expression levels of CDK4 in a human synovial sarcoma tissue microarray (TMA) by immunohistochemistry (IHC), and evaluated the correlation between CDK4 expression and the pathological characteristics of the synovial sarcoma patients. The expression levels of CDK4 were graded based on the distribution (1 < 10%, 2 = 10–25%, 3 = 26–50%, 4 = 51–75%, 5 > 75%) with score  $\geq 3$  considered high expression.

The IHC results demonstrate that CDK4 immunoreactivity is in the nucleus of synovial sarcoma tissue cells (Fig. 2c). Of the 50 TMA cases of synovial sarcoma, 41 (82.0%) of the tissues express detectable CDK4 expression. Following evaluation of the clinical history of the



human synovial sarcoma specimens, no significant correlations are found between the expression of CDK4 and patient age, gender, tissue type, or tumor location (Supplementary Table 1). However, we find that CDK4 expression significantly correlated with the clinical stage and TNM grade of the synovial sarcoma (both  $P < 0.05$ ). As shown, CDK4 expression is significantly higher in the higher clinical stages ( $\geq$ IIB) compared with those in the lower clinical stages ( $<$ IIB) (Fig. 2a). Moreover, CDK4 expression is significantly higher in the higher TNM grade ( $\geq$ G2) tissues, compared to the lower TNM grade ( $<$ G2) tissues (Fig. 2b).

Considering the absence of information available about the patients' follow-up and clinical outcomes of the synovial sarcoma TMA, we correlated the CDK4 expression levels to the clinical prognosis of the various types of sarcoma TMA. Various types of sarcoma TMA specimens were also assessed for CDK expression and localization, demonstrating varying degrees of CDK4 staining in the cell nucleus (Fig. 3c). Among the tested 59 sarcoma TMA cases, 52 (88.1%) of the tissues express CDK4. Based on data from up to 112 months of follow-up, CDK4 expression levels in samples from non-survivors are significantly higher than those from survivors (Fig. 3a). Importantly, Kaplan–Meier survival analysis shows that

the outcomes for patients in the CDK4 high-staining ( $\geq 3$ ) group are worse than for those in the CDK4 low-staining ( $< 3$ ) group (Fig. 3b). In patients with sarcomas, high CDK4 expression is associated with shorter overall survival period vs. low CDK4 expression ( $P < 0.05$ ). On further analysis, significant correlations are not found between CDK4 expression and sarcoma patient age, gender, sarcoma type, and tumor location (Supplementary Table 2).

#### CDK4 silencing with specific siRNAs suppresses cell proliferation and enhances apoptotic effect in synovial sarcoma cell lines

To validate the effect of CDK4/6-Rb pathway in synovial sarcomas in vitro, we knocked down expression of CDK4 using two CDK4 specific siRNAs. As shown by MTT assays, after transfection with increasing concentrations of CDK4 siRNA #SASI\_Hs01\_00122488 (Fig. 4a, b) and CDK4 siRNA #SASI\_Hs01\_00122490 (Suppl. Figures 1A and 1B) for 5 days, the cell viability is dose-dependently inhibited in both SYO-1 and Fuji cells, which is not observed in the nonspecific siRNA transfected cells. Furthermore, western blotting shows that CDK4 siRNA transfection significantly reduces CDK4 expression, whereas the expression of CDK6 remains unchanged. The


expression of p16<sup>INK4A</sup> is undetectable in SYO-1 and Fuji cell lines (Fig. 4c, d, Suppl. Figures 1C and 1D). After transfection with CDK4 siRNA for 48 h, the expression of pRb is reduced in a dose-dependent manner, whereas the Rb expression is not significantly changed (Fig. 4c, d, Suppl. Figures 1C and 1D). A dose-dependent decrease in the expression of the anti-apoptotic protein, Bcl-xL, is also observed after transfection with CDK4 siRNA (Fig. 4c, d, Suppl. Figures 1C and 1D).


**Palbociclib inhibits cell proliferation and promotes apoptosis by targeting the CDK4/6-Rb pathway in human synovial sarcoma cells**

Cell proliferation and growth were determined by MTT assays in synovial sarcoma SYO-1 and Fuji cells with palbociclib treatment. After exposure to increasing

concentrations of palbociclib for 2, 4, and 6 days, the cell viability is decreased in a dose-dependent manner in both SYO-1 (Fig. 5a) and Fuji cells (Fig. 5b). Morphologic changes are also observed after 2 days of palbociclib exposure. When treated with increased doses of palbociclib (0, 0.625, 1.25, 2.5, 5, 10 μM) for 48 h, SYO-1 and Fuji cells show pronounced morphologic signs of toxicity, including abnormal shape and appearance, cellular lysis, and destruction. The cells begin to show observable signs of toxicity in the form of cells reduction and abnormal cell morphology when treated with 1.25 μM palbociclib, and cellular death and other abnormalities become more pronounced as the drug concentration continued to increase up to 10 μM (Fig. 6a).

As shown by western blotting analysis, 2 days of palbociclib exposure significantly decreases the expression of pRb (Ser795, 780 and 807/811) in a dose-dependent






manner, whereas the expression of Rb is not significantly changed (Fig. 6b, c). All of the cell line samples show no p16<sup>INK4A</sup> expression. A dose-dependent decrease in the expression of the cell anti-apoptotic protein, Bcl-xL, is also observed with palbociclib treatment. Notably, western blotting shows that the activity of palbociclib had no influence on the expression of CDK4, CDK6 or cyclin D1, suggesting that palbociclib only suppresses the activity of CDK4, but does not change the protein expression (Fig. 6b, c).

#### Inhibition of CDK4/6-Rb pathway with palbociclib induces human synovial sarcoma cell cycle arrest and cell apoptosis

Due to high concentrations of palbociclib resulting in pronounced cell death, we used a 1  $\mu\text{M}$  for assessing the

cell cycle. After 1  $\mu\text{M}$  of palbociclib treatment for 24 h, a significant G1 cell-cycle arrest accompanied by a reduction in the fraction of cells in S phase is observed in both SYO-1 and Fuji cells (both  $P < 0.05$ ), compared with the non-treated control (Fig. 5c, d). This suggests that CDK4/6-Rb inhibition, induced by palbociclib, is able to promote G1 cell-cycle arrest and inhibit DNA synthesis in synovial sarcoma cells. The cell apoptosis analysis demonstrates increased apoptosis rates in both SYO-1 and Fuji cells after palbociclib exposure for 24 h, as compared with the control group (Suppl. Figures 2A and 2B). Collectively, these results indicate that reduced synovial sarcoma cell proliferation by inhibition of CDK4/6-Rb pathway is associated with induction of cell cycle arrest and cell apoptosis.



**Fig. 4 CDK4/6-Rb pathway inhibition induced by CDK4 specific siRNA (#SASI\_Hs01\_00122488) decreases cell proliferation and promotes apoptosis in synovial sarcoma cells.** Human synovial sarcoma SYO-1 and Fuji cells were transfected with increasing concentrations of CDK4 specific siRNA (#SASI\_Hs01\_00122488) or nonspecific siRNA, and cell proliferation and growth was determined subsequently. **a, b** Cell viability was determined by MTT assay after siRNA transfection for 5 days. **c, d** The respective proteins of CDK4/6-Rb-apoptosis pathway in cells were examined by Western blotting after 48 h of siRNA transfection. \*\* $P < 0.01$  compared with the cell only group


#### Inhibition of the CDK4/6-Rb pathway with palbociclib reduces human synovial sarcoma cell migration in vitro

The wound healing assay was performed in SYO-1 and Fuji cells after palbociclib treatment. After exposure to 1  $\mu$ M of palbociclib for 24, 48, and 72 h, the cell migration activities are significantly and time-dependently suppressed in both SYO-1 and Fuji cells, as compared with the palbociclib-free control groups ( $P < 0.01$ ) (Fig. 7).

#### Discussion

The CDK4/6-Rb pathway is a fundamental driver for cell cycle control and regulation of cellular apoptosis<sup>28,29</sup>, and could serve as a promising therapeutic target in various human malignancies<sup>30–34</sup>. Since its activity plays a crucial role in the proliferation and progression of cancer, pharmacological inhibitors targeting the CDK4/6 pathway have emerged as an attractive approach in oncology<sup>35,36</sup>. In the current study, we explore the expression and function of the CDK4/6-Rb pathway in synovial sarcomas, and investigate the therapeutic potential of the selective CDK4 inhibitor, palbociclib, in vitro.


We first analyzed the expression levels of CDK4 in synovial sarcoma cell lines and found that CDK4 was highly expressed in all the human synovial sarcoma cell lines, and it was found to be localized to the nucleus by immunofluorescence staining. While previous studies have assessed the expression of CDK4 in some sarcoma types, including liposarcoma and Ewing's sarcoma<sup>37,38</sup>, none of these studies have assessed the expression of CDK4 in synovial sarcoma. A study by Vlenterie et al, 2016, has analyzed the expression of cyclin D1 and nuclear phosphor-Rb in 43 synovial sarcoma tissue samples, however, this study did not characterize the relationship between the level of CDK4 expression and the clinical characteristics of the patients<sup>27</sup>. In our study, synovial sarcoma TMAs determined by IHC showed that CDK4 expression was observed in most of the tested sarcoma tissue samples. This suggests CDK4 might have an important role in the pathogenesis of synovial sarcoma. Further studies explored the relationship between CDK4 expression and clinicopathological characteristics using a TMA containing 50 synovial sarcoma cases with clinical



information, and a TMA containing 59 various sarcoma cases with up to 112 months of follow-up data. Our results showed that CDK4 expression significantly correlated with a higher clinical stage and a higher TNM grade of synovial sarcoma patients, and a worse clinical prognosis of sarcoma patients. A previous study of liposarcoma supports that the overexpression of CDK4 is correlated to a poorer prognosis of patients<sup>39</sup>. A knock-down of CDK4 in fusion-gene positive rhabdomyosarcoma cells has also been shown to abrogate transformation and proliferation *via* G1-phase cell-cycle arrest, demonstrating that CDK4 is also essential for sarcoma cell survival and growth<sup>40</sup>. More recently, amplification and over-activation of the CDK4/Rb pathway has been found in another sarcoma type, chordoma<sup>41</sup>. Altogether, these results verify the expression of CDK4 in

synovial sarcomas and highlight its important role in sarcomas, including synovial sarcoma.

In contrast to the previous study that only investigated cyclin D1 and pRb levels following palbociclib treatment<sup>27</sup>, we specifically knocked down CDK4 expression with CDK4 siRNAs to investigate the role of CDK4 in synovial sarcoma cell growth and proliferation. The result showed that CDK4 inhibition by siRNA decreased synovial sarcoma cell proliferation and growth in a dose-dependent manner. We further suppressed the expression of CDK4 in synovial sarcoma cells using the clinically approved CDK4 inhibitor, palbociclib, and explored changes to the cellular phenotypic. Consistently, our findings demonstrated that CDK4 inhibition by palbociclib reduced synovial sarcoma cell proliferation and growth dose-dependently. We demonstrated that




palbociclib was acting through inhibition of CDK4/6 activity, not by reducing protein expression. These findings collectively suggest that CDK4 plays a crucial role in promoting synovial sarcoma proliferation and growth.

As a fundamental cell division modulator, CDK4 functions mainly through activation, by phosphorylation, of the retinoblastoma tumor suppressor, inducing G1 cell cycle arrest in tumor cells<sup>42</sup>. In response to mitogenic signals, CDK4 combines with cyclin D1 and transfers into the nucleus to form the active cyclin D1–CDK4 complex and then phosphorylates Rb into pRb. Our immunofluorescence staining showed that CDK4 expression was observed both in the cytoplasm and in the nucleus of SYO-1 and Fuji cells, but mostly localized in the nucleus. It has been suggested that in proliferating cells, during G1 phase, cyclin D1 accumulates in the nucleus and triggers the active cyclin D1-CDK4 complex formation<sup>43</sup>. This leads to release of the E2F transcription factor and activation of downstream target genes, promoting cell cycle progression and ultimately cell proliferation and growth<sup>44</sup>. Notably, the cyclin D/CDK4/Rb pathway is universally disrupted in human cancer<sup>45,46</sup>. Thus, we explored changes occurring in proteins of the cyclin D/CDK4/Rb

pathway after CDK4 inhibition. We found that both the CDK4 specific siRNA and palbociclib suppressed downstream Rb phosphorylation and also reduced expression of the cell-survival protein Bcl-xL, in a dose-dependent manner. Bcl-xL is a member in Bcl-2 family, which is known to suppress downstream activators of apoptosis<sup>47</sup>. Interestingly, synovial sarcomas are known to have high levels of Bcl-2 compared to other soft tissue sarcomas<sup>48</sup>. Notably, while palbociclib acted only to inhibit CDK4 activity, with no changes to protein expression, it also effectively downregulated pRb and Bcl-xL expression.

To demonstrate the potential mechanisms underlying CDK4 inhibition caused by palbociclib treatment on synovial sarcoma cell growth, flow cytometry analysis was used to assess the cell cycle and apoptosis in human synovial sarcoma cells following treatment with palbociclib. The results revealed that CDK4 inhibition dramatically induced cell cycle arrest in G1 phase in synovial sarcoma cells after palbociclib treatment. Cell apoptosis determination simultaneously revealed that CDK4 inhibition dramatically induced cell apoptosis in synovial sarcoma cells. Hence, these findings confirmed that CDK4 inhibition, triggered by palbociclib, could decrease





synovial sarcoma cell proliferation and growth *via* induction of cell apoptosis via arresting the cell cycle in G1 phase.

p16<sup>INK4A</sup>, encoded by cyclin-dependent kinase inhibitor 2A (CDKN2A) tumor suppressor gene, is one of the first genes noted to be silenced epigenetically in human cancers<sup>49</sup>. Specific somatic loss of p16<sup>INK4A</sup> through point mutations or small deletions, and silencing of p16<sup>INK4A</sup> through promoter methylation, have been reported at high frequency in many human cancers<sup>50,51</sup>. Restriction of cell cycle progression occurs through inhibition of the activity of CDK4 by p16<sup>INK4A</sup><sup>37</sup>. A deletion of p16<sup>INK4A</sup> causes altered activity of CDK4, leading to hyperphosphorylation of Rb and aberrant regulation of the cell

cycle<sup>52,53</sup>. Preclinical data indicates that cancers with a loss in p16<sup>INK4A</sup> may still be sensitive to CDK4 inhibition<sup>54,55</sup>. Palbociclib has been shown to inhibit the growth of doxorubicin-resistant Ewing’s sarcoma patient-derived orthotopic xenografts in vivo, with a p16<sup>INK4A</sup>-deletion<sup>56</sup>. Specific orthotopic mouse models developed from sarcoma patients, may help in the development of individualized therapeutics to precisely target patient specific sarcomas<sup>57–61</sup>. In synovial sarcoma, the deletion of p16<sup>INK4A</sup> is also a frequent genetic event<sup>62</sup>. This study shows that synovial sarcoma cells, with a loss in P16<sup>INK4A</sup>, are sensitive to palbociclib treatment, indicating that palbociclib may be a potential therapeutic drug to treat synovial sarcoma.

The development of tumor cell invasion and metastasis is, largely, responsible for the mortality and morbidity of cancer<sup>63</sup>. TMA analysis showed that the overexpression of CDK4 was related to higher clinical stages and higher TNM grades in synovial sarcomas and this correlated with a poorer patient prognosis in various sarcomas, indicating that CDK4 might be necessary for tumor metastasis. The course of metastasis from the primary tumor sites to distant other organs is of principal importance in the prognosis of cancer patients<sup>63</sup>. In synovial sarcoma, a high incidence of late metastasis occurs in about 50% of all cases, which significantly impacts the mortality and reduces patient survival outcomes<sup>64,65</sup>. We then further analyzed the effect of CDK4 inhibition on synovial sarcoma cell migration in vitro. Synovial sarcoma cells treated with non-lethal doses of palbociclib unveiled that CDK4 inhibition reduced synovial sarcoma cell migration, suggesting that CDK4 might be a promotor to synovial sarcoma metastasis, which is the main obstacle in the treatment of synovial sarcoma.

Taken together, our current study demonstrates that CDK4 is highly expressed in synovial sarcomas. Overexpression of CDK4 correlates with higher clinical stages and higher TNM grades in synovial sarcomas and poor survival outcomes of sarcoma patients. CDK4 inhibition decreases synovial sarcoma cell proliferation and growth through apoptosis induction via cell cycle arrest. These findings, together with the current clinical application of palbociclib for other malignancies, highlight CDK4 as a potential therapeutic target and palbociclib as a promising anti-cancer agent for synovial sarcoma treatment.

## Materials and methods

### Cell lines and cell culture

The human synovial sarcoma cell lines SYO-1 and Fuji were kindly provided by Dr. Akira Kawai (National Cancer Center Hospital, Tokyo, Japan) and Dr. Kazuo Nagashima (Hokkaido University School of Medicine, Hokkaido, Japan), respectively<sup>66,67</sup>. The human synovial sarcoma cell lines Yamato-SS and Aska-SS were generously provided by Dr. Kazuyuki Itoh (Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan)<sup>68</sup>. All synovial sarcoma cell lines were cultured in RPMI-1640 (Life Technologies, Grand Island, NY) complete media supplemented with 10% fetal bovine serum (GIBCO, Grand Island, NY, USA), 100 U/mL penicillin G, and 100 µg/mL streptomycin (Life Technologies, Carlsbad, CA). All cells were incubated in a humidified 5% CO<sub>2</sub>-95% air atmosphere at 37 °C.

### Immunofluorescence assay

For immunostaining of cultured synovial sarcoma cells, SYO-1 and Fuji cells were grown in 6-well plates for 2 days and fixed with 3.7% paraformaldehyde for 15 min,

followed by permeabilization with ice-cold methanol and blocked with 1% bovine serum albumin (BSA). The cells were then incubated with the CDK4 primary antibody (1:200 dilution, #12790, Cell Signaling Technology, Beverly, MA, USA) and β-Actin (1:200 dilution, #sc-47778, Santa Cruz Biotechnology, Dallas, TX, USA) at 4 °C overnight, followed by incubation with Alexa Fluor 488 (Green) conjugated goat anti-rabbit antibody and Alexa Fluor 594 (Red) goat anti-mouse antibody (Invitrogen, Carlsbad, CA, USA) for 1 h. Finally, cells were imaged on a Nikon Eclipse Ti-U fluorescence microscope (Diagnostic Instruments Inc., NY, USA) equipped with a SPOT RT™ digital camera.

### Immunohistochemistry analysis of human tissue microarray (TMA)

The expression of CDK4 in the human tissue microarray was determined by immunohistochemistry assay (Paraffin) according to the manufacturer's instructions (Cell Signaling Technology, Beverly, MA, USA). The synovial sarcoma TMA (US Biomax, Inc., Rockville, MD, USA) contains 50 cases/100 cores with histopathologic data, including age, gender, tissue type, tumor location, clinical stage, TNM grade, and pathology type. The synovial sarcoma TMA information is available at the website ([http://www.biomax.us/tissue-arrays/Soft\\_Tissue/SS1001](http://www.biomax.us/tissue-arrays/Soft_Tissue/SS1001)). The various sarcomas TMAs were purchased from SuperBioChips Laboratories (Seoul, South Korea) and contain 59 paraffin-embedded tumor specimens from 59 individual sarcoma patients. Clinicopathological information including age, gender, sarcoma type, tumor location, the follow-up time and prognostic outcome can be obtained from the website (<http://www.tissue-array.com>). Hematoxylin and Eosin stained tissue array slides were made available online by the manufacturers.

Briefly, the two 5 µm paraffin-embedded TMA slides were baked for 1 h at 60 °C, deparaffinized in xylene three times for 10 min each, and then transferred through graded ethanol (100 and 95%) twice for rehydration, 10 min each. After heat-induced epitope retrieval, the endogenous peroxidase was quenched by 3% hydrogen peroxide. Following blocking by normal goat serum for 1 h at room temperature, the two slides were incubated with rabbit polyclonal antibody to human CDK4 (#12790, 1:500 dilution, Cell Signaling Technology, Beverly, MA, USA) at 4 °C overnight in a humidified chamber. Subsequently, bound antibody on the array was detected by SignalStain® Boost Detection Reagent (Cell Signaling Technology, Beverly, MA, USA) and SignalStain® DAB (Cell Signaling Technology, Beverly, MA, USA). The nuclei of synovial sarcoma cells were counterstained with hematoxylin QS (Vector Laboratories, Burlingame, CA, USA) to improve images. Finally, the section was mounted with VectaMount AQ (Vector Laboratories,

Burlingame, CA, USA) for long-term preservation. The TMA slides were also stained in the absence of CDK4 antibody to evaluate nonspecific secondary antibody reactions. The slide was imaged using an Olympus microscope (BX51, Olympus, PA, USA).

Immunostaining of the whole slide areas were viewed and scored separately by three independent pathologists who were blinded to tumor characteristics and core case details. The expression level of CDK4 was evaluated according to the percentage of cells with positive nuclear staining. Staining patterns were categorized on a semi-quantitative scale from 0–5+, as follows: 0, no nuclear staining; 1+, <10% of positive cells; 2+, 10–25% of positive cells; 3+, 26–50% of positive cells; 4+, 51–75% of positive cells; 5+, >75% of positive cells. Tumors with a staining score of  $\geq 3$  were designated as high CDK4 expression and  $< 3$  were designated as low CDK4 expression.

#### Synthetic CDK4 siRNA transfection and drug treatment

CDK4 knockdown was performed by CDK4 specific siRNA transfection in synovial sarcoma cells. The human nonspecific siRNA and CDK4 siRNAs (#SASI\_Hs01\_00122488, NM\_000075.2, 5'-CUCUUAU-CUACAUAAGGAU-3' and #SASI\_Hs01\_00122490, NM\_000075.2, 5'-CACUUACACCCGUGGUUGU-3') were purchased from Sigma-Aldrich (St. Louis, MO, USA). The nonspecific siRNA oligonucleotides were used as negative controls. Increasing concentrations (0, 10, 30, and 60 nM) of CDK4 siRNAs or nonspecific siRNA (60 nM) were transfected into cells using Lipofectamine<sup>®</sup> RNAiMAX Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. After 48 h for western blotting or 5 days for MTT assay, transfected cells were subjected to subsequent analysis.

CDK4 inhibition in synovial sarcoma cells was carried out by palbociclib treatment. Palbociclib (PD-0332991) HCl (#S1116, Selleck Chemicals, Houston, TX, USA) is a highly selective inhibitor of CDK4/6 activity. SYO-1 and Fuji cells were grown on 96-well plates for cell proliferation assays, 6-well plates for wound healing assays, or 12-well plates for western blotting analysis, and incubated with various concentrations of palbociclib, followed by subsequent experiments.

#### Cell proliferation assay

SYO-1 and Fuji cells were seeded into 96-well plates at a density of  $4 \times 10^3$  cells per well, and treatments were performed for 5 days after CDK4 siRNA transfection or 2, 4, and 6 days after palbociclib treatment, the cell viability of SYO-1 and Fuji cells was determined using MTT assays. Briefly, at the end of cell treatment, 20  $\mu$ L of MTT (5 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) was added to each well and the 96-well plates were incubated at

37 °C in a 5% CO<sub>2</sub>-95% air humidified atmosphere for 4 h. Finally, the resulting formazan product was dissolved with 100  $\mu$ L of acid isopropanol and the absorbance at a wavelength of 490 nm (A490) was measured on a SpectraMax Microplate<sup>®</sup> Spectrophotometer (Molecular Devices LLC, Sunnyvale, CA, USA). In all experiments, the MTT assays were conducted in triplicate. Meanwhile, light microscope images of the morphological changes of the SYO-1 and Fuji cells were obtained by a Zeiss microscope (Carl Zeiss, Inc., Oberkochen, Germany) with an attached Nikon D40 digital camera (Diagnostic Instruments Inc., NY, USA) equipped with a Zen Imaging software after increasing concentrations (0, 0.625, 1.25, 2.5, 5, 10  $\mu$ M) of palbociclib treatment for 48 h.

#### Protein preparation and Western blotting

Protein lysates were extracted from SYO-1 and Fuji cells with 1 $\times$  RIPA lysis buffer (Upstate Biotechnology, Charlottesville, VA, USA) supplemented with complete protease inhibitor cocktail tablets (Roche Applied Science, Indianapolis, IN, USA). The concentrations of the protein lysates were determined by DC<sup>TM</sup> protein assay reagents (BIO-RAD, Hercules, CA, USA) with a Beckman spectrophotometer (Beckman Instruments, Inc., Indianapolis, IN, USA). Equal concentrations of denatured proteins were separated by NuPAGE<sup>®</sup> 4–12% Bis-Tris Gel (Invitrogen, Carlsbad, CA, USA), and then transferred to nitrocellulose membranes (BIO-RAD, Hercules, CA, USA). After blocking with 5% non-fat milk for 1 h, the membranes were incubated with rabbit monoclonal antibodies to human CDK4, CDK6, cyclin D1, p16<sup>INK4A</sup>, pRb (Ser795, 780 and 807/811), and Bcl-xL (1:1000 dilution, Cell Signaling Technology, Beverly, MA, USA), mouse monoclonal antibodies to human Rb (1:1000 dilution, Cell Signaling Technology, Beverly, MA, USA) and  $\beta$ -actin (1:2000 dilution, Santa Cruz Biotechnology, Dallas, TX, USA) at 4 °C overnight. Following primary antibody incubation, the membranes were washed with TBST for 3 times, 5 min every time, and Goat anti-rabbit IRDye<sup>®</sup> 800CW (926-32211, 1:5000 dilution, Li-COR Biosciences, NE, USA) or Goat anti-mouse IRDye<sup>®</sup> 680LT secondary antibody (926-68020, 1:10000 dilution, Li-COR Biosciences, NE, USA) were added, respectively. After incubation at room temperature for 2 h, the bands were detected using Odyssey Infrared Fluorescent Western Blots Imaging System from Li-COR Bioscience (Lincoln, NE, USA). Quantification of Western blotting results was analyzed using Odyssey software 3.0 (Li-COR Bioscience, Lincoln, NE, USA).

#### Flow cytometry analysis

The cell cycle status of SYO-1 and Fuji cells were analyzed by flow cytometry after 24 h of palbociclib

treatment. SYO-1 and Fuji cells were collected and fixed in 70% ethanol at 4 °C overnight, followed by incubation with RNase A (100ug/mL, Thermo Scientific, Waltham, MA, USA) at 37 °C for 30 min and stained with Propidium Iodide (50ug/mL, Sigma-Aldrich, St. Louis, MO, USA) for an additional 30 min. The DNA content was determined by flow cytometry (FACSCanto II, BD, NJ, USA) and the population of cells in each phase of the cell cycle analyzed with the MultiCycle software (Phoenix Flow Systems, CA, USA).

Cell apoptosis in SYO-1 and Fuji cells were analyzed by flow cytometry after 24 h of palbociclib treatment. For cell apoptosis analysis, the cells were collected by trypsinization and resuspended in annexin-binding buffer, followed by staining with FITC annexin V and Propidium Iodide (Invitrogen, NY, USA) for 30 min, and then subjected to flow cytometry analysis.

### Cell migration assay

Cell migration activity was detected by wound healing assays. SYO-1 and Fuji cells were seeded into 6-well plates at a density of  $4 \times 10^5$  cells per well and incubated overnight. After cells reached 100% confluency, the adherent cell layer was wounded by scraping three parallel lines with a sterile 10  $\mu$ L tip, and 1  $\mu$ M of palbociclib was immediately added into the cell medium for an additional starved incubation with low-serum medium containing 2% FBS, since serum starving is the most common non-pharmaceutical method for minimizing proliferation in wound healing assays<sup>69,70</sup>. Wounds were observed at 0, 24, 48 and 72 h after palbociclib treatment. The wounded cells within each well were photographed each time point under a Zeiss microscope (Carl Zeiss, Inc., Oberkochen, Germany) with an attached Nikon D40 digital camera (Diagnostic Instruments Inc., NY, USA) equipped with Nikon Camera Control Pro 2 Imaging software (Diagnostic Instruments Inc., NY, USA). The wound width was evaluated by measuring the distance between the two edges of the scratch at five sites in each image. Cell migration was determined using the following formula: Percentage of wound healing (%) = (wound width at the 0 h time point – wound width at the observed time point) / wound width at the 0 h time point  $\times$  100%.

### Statistical analysis

Statistical analysis was performed using the GraphPad PRISM 5 software (GraphPad Software, San Diego, CA, USA). Data are expressed as mean  $\pm$  SD. Student's *t*-test was used to determine the statistical significance of differences between groups. Survival analysis was assessed using the Kaplan-Meier method, and significance was determined by the log-rank test. A *P* value of  $\leq 0.05$  was considered statistically significant.

### Acknowledgements

X.L. is supported by a scholarship from the China Scholarship Council (201606370194). Z.D. is supported, in part, through a Grant from Sarcoma Foundation of America (SFA) (222433), and a Grant from National Cancer Institute (NCI)/National Institutes of Health (NIH), U01, CA151452-01.

### Authors' contributions

Conception and design: F.J.H., Z.D. Development of methodology: X.L., Z.D. Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): X.L., N.A.S., C.G., H.M., P.G., F.J.H., Z.D. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): X.L., N.A.S., C.G., H.M., P.G., Z.D. Writing, review, and/or revision of the manuscript: X.L., N.A.S., C.G., Z.D. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): T.X., F.J.H., Z.D. Study supervision: T.X., F.J.H., Z.D.

### Author details

<sup>1</sup>Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, David Geffen School of Medicine at University of Los Angeles, Los Angeles, CA 90095, USA. <sup>2</sup>Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China. <sup>3</sup>Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

### Conflicts of interest

The authors declare that they have no conflict of interest.

### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Supplementary Information** accompanies this paper at (<https://doi.org/10.1038/s41419-018-0474-4>).

Received: 15 January 2018 Revised: 6 March 2018 Accepted: 9 March 2018  
Published online: 18 April 2018

### References

1. Choong, P. F., Rydholm, A. & Gustafson, P. Patients with soft-tissue sarcomas. *Ann. Surg.* **221**, 203–205 (1995).
2. Clark, J. et al. Identification of novel genes, SYT and SSX, involved in the t(X;18) (p11.2; q11.2) translocation found in human synovial sarcoma. *Nat. Genet.* **7**, 502–508 (1994).
3. Crew, A. J. et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. *Embo. J.* **14**, 2333–2340 (1995).
4. Spillane, A. J., A'Hern, R., Judson, I. R., Fisher, C. & Thomas, J. M. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. *J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.* **18**, 3794–3803 (2000).
5. Lewis, J. J. et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. *J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.* **18**, 2087–2094 (2000).
6. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* **144**, 646–674 (2011).
7. Liao, Y., Feng, Y., Shen, J., Hornicek, F. J. & Duan, Z. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma. *Cancer Metastasis Rev.* **35**, 151–163 (2016).
8. O'Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4/6 inhibitors. *Nat. Rev. Clin. Oncol.* **13**, 417–430 (2016).
9. Spring, L., Bardia, A. & Modi, S. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. *Discov. Med.* **21**, 65–74 (2016).
10. Knudsen, E. S. & Knudsen, K. E. Tailoring to RB: tumour suppressor status and therapeutic response. *Nat. Rev. Cancer* **8**, 714–724 (2008).

11. Classon, M. & Harlow, E. The retinoblastoma tumour suppressor in development and cancer. *Nat. Rev. Cancer* **2**, 910–917 (2002).
12. Blain, S. W. Switching cyclin D-Cdk4 kinase activity on and off. *Cell Cycle* **7**, 892–898 (2008).
13. Baker, S. J. & Reddy, E. P. CDK4: A Key Player in the Cell Cycle, Development, and Cancer. *Genes & Cancer* **3**, 658–669 (2012).
14. Hamilton, E. & Infante, J. R. Targeting CDK4/6 in patients with cancer. *Cancer Treat. Rev.* **45**, 129–138 (2016).
15. Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: From Discovery to Therapy. *Cancer Discov.* **6**, 353–367 (2016).
16. Yoo, J., Park, S. Y., Kang, S. J., Shim, S. I. & Kim, B. K. Altered expression of G1 regulatory proteins in human soft tissue sarcomas. *Arch. Pathol. Lab. Med.* **126**, 567–573 (2002).
17. Finn, R. S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol.* **16**, 25–35 (2015).
18. Ozaki, A., Tanimoto, T. & Saji, S. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. *N. Engl. J. Med.* **373**, 1672–1673 (2015).
19. Turner, N. C. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. *N. Engl. J. Med.* **373**, 209–219 (2015).
20. Beaver, J. A. et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. *Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.* **21**, 4760–4766 (2015).
21. Walker, A. J. et al. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. *Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.* **22**, 4968–4972 (2016).
22. Barroso-Sousa, R., Shapiro, G. I. & Tolaney, S. M. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. *Breast Care* **11**, 167–173 (2016).
23. VanArsdale, T., Boshoff, C., Arndt, K. T. & Abraham, R. T. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. *Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.* **21**, 2905–2910 (2015).
24. Lim, J. S., Turner, N. C. & Yap, T. A. CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. *Cancer Discov.* **6**, 697–699 (2016).
25. Dickson, M. A. et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. *J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.* **31**, 2024–2028 (2013).
26. Dickson, M. A. et al. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. *JAMA Oncol.* <https://doi.org/10.1001/jamaoncol.2016.0264> (2016).
27. Vletterie, M. et al. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients. *Ann. Surg. Oncol.* **23**, 2745–2752 (2016).
28. Bloom, J. & Cross, F. R. Multiple levels of cyclin specificity in cell-cycle control. *Nat. Rev. Mol. Cell. Biol.* **8**, 149–160 (2007).
29. Rossi, A. G. et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. *Nat. Med.* **12**, 1056–1064 (2006).
30. Wander, S. A., Mayer, E. L. & Burstein, H. J. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. *J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.* **35**, 2866–2870 (2017).
31. Olmez, I. et al. Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms. *Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.*, <https://doi.org/10.1158/1078-0432.CCR-17-0803> (2017).
32. Cook Sangar, M. L. et al. Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models. *Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.*, <https://doi.org/10.1158/1078-0432.CCR-16-2943> (2017).
33. Kong, Y. et al. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma indicate the potential for CDK4/6 Inhibitors in Targeted Therapy. *Clinical cancer research: an official journal of the American Association for Cancer Research*, <https://doi.org/10.1158/1078-0432.CCR-17-0070> (2017).
34. Luke, J. J. et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. *Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.* **18**, 2638–2647 (2012).
35. Patnaik, A. et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. *Cancer Discov.* **6**, 740–753 (2016).
36. Finn, R. S. et al. Palbociclib and Letrozole in Advanced Breast Cancer. *N. Engl. J. Med.* **375**, 1925–1936 (2016).
37. Perez, M., Munoz-Galvan, S., Jimenez-Garcia, M. P., Marin, J. J. & Carnero, A. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. *Oncotarget* **6**, 40557–40574 (2015).
38. Kammerer-Jacquet, S. F. et al. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry. *Hum. Pathol.* **59**, 34–40 (2017).
39. Saada-Bouzid, E. et al. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. *Mod. Pathol.* **28**, 1404–1414 (2015).
40. Olanich, M. E. et al. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma. *Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.* **21**, 4947–4959 (2015).
41. von Witzleben, A. et al. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmacological Inhibitors of the CDK4/6 Cell-Cycle Pathway. *Cancer Res.* **75**, 3823–3831 (2015).
42. Johnson, J. et al. Targeting the RB-E2F pathway in breast cancer. *Oncogene*, <https://doi.org/10.1038/onc.2016.32> (2016).
43. Matsushime, H. et al. D-type cyclin-dependent kinase activity in mammalian cells. *Mol. Cell. Biol.* **14**, 2066–2076 (1994).
44. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. *J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.* **24**, 1770–1783 (2006).
45. Dickson, M. A. Molecular pathways: CDK4 inhibitors for cancer therapy. *Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.* **20**, 3379–3383 (2014).
46. Witkiewicz, A. K. & Knudsen, E. S. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. *Breast Cancer Res.* **16**, 207 (2014).
47. Schott, A. F., Apel, I. J., Nunez, G. & Clarke, M. F. Bcl-XL protects cancer cells from p53-mediated apoptosis. *Oncogene* **11**, 1389–1394 (1995).
48. Hirakawa, N., Naka, T., Yamamoto, I., Fukuda, T. & Tsuneyoshi, M. Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. *Hum. Pathol.* **27**, 1060–1065 (1996).
49. Sheppard, K. E. & McArthur, G. A. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. *Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.* **19**, 5320–5328 (2013).
50. Ruas, M. & Peters, G. The p16INK4a/CDKN2A tumor suppressor and its relatives. *Biochim. Biophys. Acta* **1378**, F115–F177 (1998).
51. Forbes, S. et al. Cosmic 2005. *Br. J. Cancer* **94**, 318–322 (2006).
52. Ho, A. & Dowdy, S. F. Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. *Curr. Opin. Genet. Dev.* **12**, 47–52 (2002).
53. Lundberg, A. S. & Weinberg, R. A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. *Mol. Cell. Biol.* **18**, 753–761 (1998).
54. Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. *Mol. Cancer Ther.* **3**, 1427–1438 (2004).
55. Eilers, G. et al. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. *Mol. Cancer Ther.* **14**, 1346–1353 (2015).
56. Murakami, T. et al. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. *Oncotarget* **7**, 47556–47564 (2016).
57. Igarashi, K. et al. A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. *Oncotarget* **8**, 62111–62119 (2017).
58. Kawaguchi, K. et al. Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. *Cell Cycle* **16**, 1063–1069 (2017).
59. Igarashi, K. et al. High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. *J. Cell. Biochem.* **118**, 2739–2743 (2017).

60. Igarashi, K. et al. Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. *Cell Cycle* **16**, 91–94 (2017).
61. Hiroshima, Y. et al. Patient-derived orthotopic xenograft (PDOX) nude mouse model of soft-tissue sarcoma more closely mimics the patient behavior in contrast to the subcutaneous ectopic model. *Anticancer. Res.* **35**, 697–701 (2015).
62. Subramaniam, M. M. et al. p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas. *Am. J. Clin. Pathol.* **126**, 866–874 (2006).
63. Jandial, R. *Metastatic cancer: clinical and biological perspectives*. (Landes Bioscience, 2013).
64. Krieg, A. H. et al. Synovial sarcomas usually metastasize after > 5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. *Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. / ESMO* **22**, 458–467 (2011).
65. Vletterie, M. et al. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. *Eur. J. Cancer* **58**, 62–72 (2016).
66. Kawai, A. et al. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. *Cancer Lett.* **204**, 105–113 (2004).
67. Nojima, T. et al. Morphological and cytogenetic studies of a human synovial sarcoma xenotransplanted into nude mice. *Acta Pathol. Jpn.* **40**, 486–493 (1990).
68. Naka, N. et al. Synovial sarcoma is a stem cell malignancy. *Stem Cells* **28**, 1119–1131 (2010).
69. Davis, P. K., Ho, A. & Dowdy, S. F. Biological methods for cell-cycle synchronization of mammalian cells. *Biotechniques* **30**, 1322–1326 (2001).
70. Jonkman, J. E. et al. An introduction to the wound healing assay using live-cell microscopy. *Cell Adh. Migr.* **8**, 440–451 (2014).